DESCRIPTION

• Notes: To generate stable TCR-expressing cells, remove the growth medium 48 hours after transduction and replace it with fresh growth medium containing the appropriate amount of puromycin for antibiotic selection of transduced cells. For more information on how to determine the concentration of antibiotic required, see our FAQs resources "what is a kill curve?" Biosafety: The lentiviruses are produced with a SIN (self-inactivation) lentivector which ensures self-inactivation of the lentiviral construct after transduction and integration into the genomic DNA of the target cells. None of the HIV genes (gag, pol, rev) will be expressed in the transduced cells, as they are expressed from packaging plasmids lacking the packing signal. Although the pseudotyped lentiviruses are replication-incompetent, they require the use of a Biosafety Level 2 facility. BPS recommends following all local federal, state, and institutional regulations and using all appropriate safety precautions. License Disclosure: Visit bpsbioscience.com/license for the label license and other key information about this product.  Troubleshooting Guide: Visit bpsbioscience.com/lentivirus-faq for detailed troubleshooting instructions. For all further questions, please email support@bpsbioscience.com.
• Shiptemp: -80°C (dry ice)
• Warnings: Avoid freeze/thaw cycles
• Category: CAR T-Cell Therapy
• Background: NY-ESO-1 (New York esophageal squamous cell carcinoma 1, also known as Cancer/testis antigen 1, or CTAG1B), is an important tumorigenic marker present in malignant cells. Normally expressed only in embryonic testis, this highly immunogenic protein is not usually found in normal tissues, but is re-expressed in multiple myeloma, non-small cell lung carcinoma, and breast and ovarian cancer, making it a promising candidate antigen for cancer immunotherapy.  Several NY-ESO-1-directed therapies are being developed including cancer vaccines, anti-NY-ESO-1 adoptive cell therapy, and NY-ESO-1-specific TCR-T cell therapy in combination with checkpoint inhibitors.
• Description: The human NY-ESO-1-specific T Cell Receptor (TCR) lentiviruses (clone 1G4) are replication incompetent, HIV-based, VSV-G-pseudotyped lentiviral particles that are ready to infect almost all types of mammalian cells, including primary and non-dividing cells. These viruses transduce cells with a human TCR (clone 1G4) that specifically recognizes antigen NY-ESO-1 (New York esophageal squamous cell carcinoma 1), and in which the TCR α chain and β chain are linked by P2A (Figure 1). The lentiviruses also transduce a puromycin selection gene. Figure 1. (A) Schematic of the lenti-vector used to generate the NY-ESO-1-specific TCR lentivirus and (B) Construct diagram showing expressed components of the NY-ESO-1-specific TCR. TRAV and TRAC correspond to the TCR alpha chain variable and constant regions, respectively, whereas TRBV and TRBC correspond to the TCR beta chain variable and constant regions.
• Formulation: The lentiviruses were produced in HEK293T cells in medium containing 90% DMEM + 10% FBS.  Virus particles can be packaged in custom formulations by special request, for an additional fee.
• Supplied As: ≥2 x 107 TU/ml. The titer will vary with each lot; the exact value is provided with each shipment.
• Unspsc Code: 41106621
• Unspsc Name: Virus mediated expression vectors or kits
• Applications: Use as a positive control for NY-ESO-1 TCR evaluation and optimize experimental conditions. Generate NY-ESO-1 TCR stable cell line (puromycin resistant).
• Product Type: Lentivirus
• Biosafety Level: BSL-2
• Storage Stability: Lentiviruses are shipped with dry ice. For long term storage, it is recommended to store the virus at -80°C. Avoid repeated freeze-thaw cycles. Titers can drop significantly with each freeze-thaw cycle.
• Scientific Category: CAR T-Cell Therapy